Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull It's hard to argue with a price this cheap. With a price-to-free cash flow ratio of less than 11, Merck's a steal.
The Motley Fool March 22, 2007 Richard Gibbons	An Incredibly Cheap Stock This company has the potential to pay off for decades. Fairfax is a great example of why value investing works.
BusinessWeek May 22, 2006 Gene G. Marcial	Raising The Roof At Champion Enterprises Who said homebuilder stocks were over? Champion Enterprises is surging, trading at 15.57, close to its 52-week high of $16.00 -- almost double its price a year ago.
The Motley Fool October 17, 2005 Rich Smith	Previews From the Trailer Park Two manufactured home companies prepare to announce third-quarter earnings. Of the two, industry watchers will likely want to focus on Champion.
The Motley Fool January 31, 2005 Stephen D. Simpson	Merck Takes Another Body Blow Loss of exclusivity on major osteoporosis drug could take steam out of the recovery process. Investors in Merck just can't catch a break.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull Rebuttal Priced at a P/E of 13 and paying you a 4.8% dividend, Merck isn't just affordable -- it's a stock you can't afford not to own.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
The Motley Fool July 25, 2006 Ryan Fuhrmann	A Champion in a Tough Industry Champion Enterprises, a manufactured housing builder, reports more sales but so-so earnings. The these results suggest a recovery is finally under way? Investors, take note.
BusinessWeek July 25, 2005 Gene G. Marcial	Is Merck Rallying After That Nasty Tumble? Although most analysts who track Merck remain bearish on the beleaguered drugmaker, some upbeat investors are buying. Why? It's Vioxx market may have softened, but its new vaccines will rise to the occasion.
This Old House Deborah Baldwin	Electric Knife Sharpeners Blades too dull to slice a tomato? Straighten up your knife edges and make them cut cleanly with the right tool for the job
AskMen.com Gregory Cartier	Knives You Need In The Kitchen A review of knives and why quality ones are worth the extra money.
The Motley Fool February 21, 2006 Rick Aristotle Munarriz	Biggest Disappointment: Merck In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: Merck is rich in cash, tradition, and potholes.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull Rebuttal Plenty of cash. Big pipeline. Not to worry. The future can't be predicted, but Merck's history shows its ability to weather even the toughest pharmaceutical-development environments.
The Motley Fool February 9, 2006 Rich Smith	Foolish Forecast: Can Champion Prevail? As demand for its manufactured home products builds in the wake of last year's hurricanes, Champion is on the comeback trail. But the company still has a few issues investors need to keep an eye on.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Rebuttal There's a reason why Merck's stock is cheap: weak pipeline, weak prospects.
The Motley Fool February 22, 2005 Charly Travers	Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list.
The Motley Fool July 21, 2006 Rich Smith	Foolish Forecast: Enter the Champion Temporary housing manufacturer Champion Enterprises reports its second-quarter 2006 results Monday. Investors, take note.
The Motley Fool October 23, 2006 Brian Lawler	Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount.
The Motley Fool January 25, 2005 Stephen D. Simpson	Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today.
The Motley Fool October 21, 2004 Brian Gorman	Merck Is Down But Not Out The pharma's woes may have silver linings. For now, the company's investors might want to sit tight.
The Motley Fool November 25, 2011 Dan Caplinger	Has Merck Become the Perfect Stock? Like most other pharma companies, Merck is dealing with the imminent loss of patent protection on one of its blockbuster drugs.
The Motley Fool January 4, 2005 Richard Gibbons	How to Outperform in 2005 Four tips to help find stocks that will beat the market in the year ahead.
The Motley Fool December 10, 2008 Brian Orelli	Merck: Same Plan, With a Twist With increasing generic competition and languishing sales of cholesterol-lowering drugs Vytorin and Zetia, Merck is doing its best to replace sales by pushing new drugs through its pipeline.
The Motley Fool October 4, 2004 Mathew Emmert	Got Merck? The pharmaceutical's investors can't seem to catch a break.
The Motley Fool August 22, 2005 Stephen D. Simpson	Vioxx Brings the Pain A jury stings Merck for hefty Vioxx damages, battering shares.
The Motley Fool September 16, 2004 Richard Gibbons	Buffett of the North Canadian insurer Fairfax Financial has been able to compound its book value at 31% annually since 1986 because of the exceptional investing abilities of its managers. For investors willing to take on some risk in search of potentially stellar returns, Fairfax is worth a look.
The Motley Fool October 24, 2005 Stephen D. Simpson	Merck Needs to Take Its Medicine It will be a long, long time before business at the pharmaceutical returns to business as usual. Turnarounds can pay off for patient investors.